Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

NCT02670213 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02670213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
March 16, 2016
Completion date
September 30, 2024
Enrollment
8 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, congenital fxiii deficiency